New Amgen Data at ESC 2022 Show Long-Term LDL-C Lowering with REPATHA® (EVOLOCUMAB) was well-tolerated for more than 8 years

THOUSAND OAKS, Calif.Aug. 29, 2022 /PRNewswire/ — Amgen (NASDAQ:AMGN) today presented new compelling data from the Phase 3 FOURIER open label extension (OLE) studies of Repatha® (evolocumab) in adults with atherosclerotic cardiovascular disease (ASCVD) during the Aug. 29 late-breaking Hot Line Session of the European Society of Cardiology (ESC) Annual Meeting being held in Barcelona, Spain, and online. These data were simultaneously published in Circulation. Repatha is the first and only proprotein convertase subtilisin/kexin type 9 inhibitor (PCSK9i) to date to show long-term clinical outcomes in patients with ASCVD for up to 8.4 years.

Read More
Back to News